Antibe Academic Collaborator to Present Clinical Data at PAINWeek 2022

– Otenaproxesul demonstrated efficacy in acute pain clinical study conducted in the UK in 2019 TORONTO–(BUSINESS WIRE)–$ATBPF–Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies that target inflammation, is pleased to announce the selection of a poster presentation of clinical data supporting otenaproxesul’s acute … [Read more…]

GlycoMimetics Appoints Edwin Rock, M.D., Ph.D. as Chief Medical Officer

ROCKVILLE, Md.–(BUSINESS WIRE)–GlycoMimetics, Inc. (Nasdaq: GLYC), a clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today announced that Edwin Rock, M.D., Ph.D. has joined the executive leadership team as Chief Medical Officer (CMO). Dr. Rock brings nearly two decades of biopharmaceutical clinical development experience, most recently serving as CMO for … [Read more…]

S2 Genomics Announces Distribution Agreement with Techtum Lab AB to Serve Scandinavia

Singulator™ 100 System and components to be available through local distributor in Norway, Finland, Denmark and Sweden. LIVERMORE, Calif.–(BUSINESS WIRE)–S2 Genomics, Inc. today announced that it has entered into a distribution agreement with Techtum Lab AB for the promotion, sales, and support of S2 Genomics’ Singulator™ 100 System and associated products for single-cell genomics and … [Read more…]

Biodesix to Participate in Two Upcoming Investor Conferences in September

BOULDER, Colo.–(BUSINESS WIRE)–$BDSX #patientsfirst—Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive Officer of Biodesix, will participate in two upcoming investor conferences: Morgan Stanley 20th Annual Global Healthcare Conference Date: Tuesday, September 13, 2022 at 9:10 a.m. ET Format: Fireside Chat and … [Read more…]

Vizient Medical Device Tech Watch Highlights Trends in AI, Treatment Options for Pulmonary Embolism and Strategies to Boost Clinical Workforce Retention

IRVING, Texas–(BUSINESS WIRE)–#teamvizient—Vizient, Inc. today released its latest Medical Device Tech Watch, identifying trends in artificial intelligence (AI), examining treatment options for pulmonary embolism and highlighting strategies to boost clinical workforce retention. The full Medical Device Tech Watch can be accessed here. “Advances in technology are having a positive impact not only on patient care … [Read more…]

Iveric Bio Announces Positive Topline Data from Zimura® GATHER2 Phase 3 Clinical Trial in Geographic Atrophy

– Primary Endpoint Met with 14.3% Reduction (p-value = 0.0064) in Mean Rate of Growth (Slope) in GA Area Over 12 Months Using Square Root Transformation; 17.7% Reduction (p-value = 0.0039) Using Observed GA Area – – Statistically Significant Result with Favorable Safety Profile – – Post-hoc Analysis of U.S. Patients: 25.5% Reduction (p-value = … [Read more…]

SINOVAC Approved to Initiate Clinical Trial for Its Omicron Containing COVID-19 Vaccine in Chile

BEIJING–(BUSINESS WIRE)–#COVID19–Sinovac Biotech Ltd. (“SINOVAC” or the “Company”) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced that the Chilean Public Health Institute (Instituto de Salud Pública, ISP) approved a phase II clinical trial for its inactivated Omicron strain COVID-19 vaccine and trivalent COVID-19 vaccine (ancestral, Delta and Omicron variants) on August 31st. … [Read more…]

Dr. Fabian Geldmacher is Director Strategy & Business Development of Lysando AG

TRIESENBERG, Liechtenstein–(BUSINESS WIRE)–#Artilysin–Lysando AG – market leader in the field of antimicrobial proteins – is pleased to announce that Fabian Geldmacher, M.D., has joined the team as Director Strategy & Business Development in June. Dr. Geldmacher will be responsible for shaping Lysando’s strategy and identifying areas where Lysando’s technology can add the most value. He … [Read more…]

Frédéric PELONG, Chief Financial Officer, Joins the Valbiotis Board of Directors

Former Chief Financial Officer in numerous mid-caps and large international groups, with over 20 years’ professional experience in France and abroad. The expertise necessary to accelerate Valbiotis’ future hypergrowth in charge of the global financial strategy. A new appointment at a milestone in the Company’s history, in preparation for commercialization. LA ROCHELLE, France–(BUSINESS WIRE)–Regulatory News: … [Read more…]

GALDERMA Showcases Its Continued Commitment to Innovation in Dermatology With New Data to Be Presented at 2022 EADV Congress

Galderma, the pure-play dermatology category leader with a 40+ year heritage in dermatology, will present one oral, six symposia and four hub sessions demonstrating its scientific expertise and ongoing commitment to advancing dermatology 18 scientific and clinical posters will unveil new data on skin disease awareness and scientific innovation in prurigo nodularis, sensitive skin, acne, … [Read more…]